Cinctive Capital Management LP Has $5.88 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Cinctive Capital Management LP decreased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 62.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,765 shares of the specialty pharmaceutical company's stock after selling 80,382 shares during the quarter. Cinctive Capital Management LP owned approximately 0.08% of Jazz Pharmaceuticals worth $5,882,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Pacer Advisors Inc. increased its position in Jazz Pharmaceuticals by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock worth $272,713,000 after buying an additional 115,102 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock worth $19,394,000 after acquiring an additional 100,112 shares in the last quarter. GW&K Investment Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 26.6% during the 4th quarter. GW&K Investment Management LLC now owns 464,003 shares of the specialty pharmaceutical company's stock valued at $57,142,000 after acquiring an additional 97,589 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Jazz Pharmaceuticals by 501.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 112,055 shares of the specialty pharmaceutical company's stock valued at $13,800,000 after acquiring an additional 93,422 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Jazz Pharmaceuticals in the 4th quarter worth approximately $11,373,000. Institutional investors own 89.14% of the company's stock.

Insider Activity

In related news, CAO Patricia Carr sold 1,140 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the sale, the chief accounting officer now owns 7,012 shares in the company, valued at $966,323.72. This trade represents a 13.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the transaction, the chief marketing officer now directly owns 82,024 shares of the company's stock, valued at $11,368,526.40. This represents a 7.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,736 shares of company stock worth $4,023,305. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock traded down $5.28 during trading on Monday, hitting $104.76. 647,534 shares of the company's stock traded hands, compared to its average volume of 950,254. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a market cap of $6.36 billion, a PE ratio of 14.77, a PEG ratio of 1.04 and a beta of 0.42. The firm's fifty day moving average price is $132.27 and its 200 day moving average price is $123.09.

Analysts Set New Price Targets

JAZZ has been the topic of a number of recent analyst reports. HC Wainwright lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Barclays reissued an "overweight" rating and set a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Truist Financial raised their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Piper Sandler reissued an "overweight" rating and set a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Finally, Cantor Fitzgerald lowered Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and raised their target price for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.